Delving into the Latest Updates on Sodium Aurothiomalate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Gold sodium thiomalate, Gold sodium thiomalate (USP), Sodium aurothiomalate (JP17)

+ [6]

Target-

Mechanism-

Therapeutic Areas

Immune System DiseasesSkin and Musculoskeletal Diseases

Active Indication

Rheumatoid ArthritisArthritis

Inactive Indication-

Originator Organization

Merck & Co., Inc.

Active Organization

Takata Seiyaku Co., Ltd.

Merck Sharp & Dohme Corp.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

JP (01 Oct 1970),

Rheumatoid Arthritis

Regulation-

Login to view timeline

Structure

Molecular FormulaC4H6AuNaO4S

InChIKeyAATVVBHCZDQBFG-UHFFFAOYSA-N

CAS Registry12244-57-4

This phase I trial studies the side effects and best dose of sirolimus and gold sodium thiomalate when given together in treating patients with advanced squamous non-small cell lung cancer (NSCLC). Sirolimus and gold sodium thiomalate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth

Start Date01 Jun 2011

Sponsor / Collaborator

Mayo Clinic

[+1]

NCT00575393 / CompletedPhase 1IIT

A Phase I Dose Escalation Study of the PKC Inhibitor, Aurothiomalate (ATM) in Patients With Advanced Non-Small Cell Lung Cancer

RATIONALE: Gold sodium thiomalate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
PURPOSE: This phase I trial is studying the side effects and best dose of gold sodium thiomalate in treating patients with advanced non-small cell lung cancer.

Start Date25 Jan 2007

Sponsor / Collaborator

Mayo Clinic

100 Clinical Results associated with Sodium Aurothiomalate

Login to view more data

100 Translational Medicine associated with Sodium Aurothiomalate

Login to view more data

100 Patents (Medical) associated with Sodium Aurothiomalate

Login to view more data

779

Literatures (Medical) associated with Sodium Aurothiomalate

01 Dec 2024·Molecular Biology Reports

Protein kinase C iota promotes glycolysis via PI3K/AKT/mTOR signalling in high grade serous ovarian cancer

Article

Author: Roy, Adhiraj ; Mandal, Supratim ; Tyagi, Komal

BACKGROUNDEpithelial ovarian cancer, especially high grade serous ovarian cancer (HGSOC) is by far, the most lethal gynecological malignancy with poor prognosis and high relapse rate. Despite of availability of several therapeutic interventions including poly-ADP ribose polymerase (PARP) inhibitors, HGSOC remains unmanageable and identification of early detection biomarkers and therapeutic targets for this lethal malady is highly warranted. Aberrant expression of protein kinase C iota (PKCί) is implicated in many cellular and physiological functions involved in tumorigenesis including cell proliferation and cell cycle deregulation.METHODS AND RESULTSTwo high grade serous ovarian cancer cells SKOV3 and COV362 were employed in this study. PKCί was genetically knocked down or pharmacologically inhibited and several functional and biochemical assays were performed. We report that PKCί is overexpressed in HGSOC cells and patient tissue samples with a significant prognostic value. Pharmacological inhibition of PKCί by Na-aurothiomalate or its shRNA-mediated genetic knockdown suppressed HGSOC cell proliferation, EMT and induced apoptosis. Moreover, PKCί positively regulated GLUT1 and several other glycolytic genes including HK1, HK2, PGK1, ENO1 and LDHA to promote elevated glucose uptake and glycolysis in HGSOC cells. Mechanistically, PKCί drove glycolysis via PI3K/AKT/mTOR signalling. Na-aurothiomalate and highly selective, dual PI3K/mTOR inhibitor dactolisib could serve as novel anti-glycolytic drugs in HGSOC.CONCLUSIONTaken together, our results indicate PKCί/PI3K/AKT/mTOR signalling cascade could be a novel therapeutic target in a lethal pathology like HGSOC.

24 May 2023·Chemical Reviews

Next Generation Gold Drugs and Probes: Chemistry and Biomedical Applications

Review

Author: Mertens, R. Tyler ; Awuah, Samuel G. ; Olelewe, Chibuzor ; Arojojoye, Adedamola S. ; Gukathasan, Sailajah

The gold drugs, gold sodium thiomalate (Myocrisin), aurothioglucose (Solganal), and the orally administered auranofin (Ridaura), are utilized in modern medicine for the treatment of inflammatory arthritis including rheumatoid and juvenile arthritis; however, new gold agents have been slow to enter the clinic. Repurposing of auranofin in different disease indications such as cancer, parasitic, and microbial infections in the clinic has provided impetus for the development of new gold complexes for biomedical applications based on unique mechanistic insights differentiated from auranofin. Various chemical methods for the preparation of physiologically stable gold complexes and associated mechanisms have been explored in biomedicine such as therapeutics or chemical probes. In this Review, we discuss the chemistry of next generation gold drugs, which encompasses oxidation states, geometry, ligands, coordination, and organometallic compounds for infectious diseases, cancer, inflammation, and as tools for chemical biology via gold-protein interactions. We will focus on the development of gold agents in biomedicine within the past decade. The Review provides readers with an accessible overview of the utility, development, and mechanism of action of gold-based small molecules to establish context and basis for the thriving resurgence of gold in medicine.

01 Jun 2022·Acta ParasitologicaQ4 · MEDICINE

Aurothiomalate-Based Drugs as Potentially Novel Agents Against Leishmania major: A Mini Review

Q4 · MEDICINE

Review

Author: Keighobadi, Masoud ; Aazadbakht, Mohammad ; Fakhar, Mahdi ; Davoodi, Ali ; Montazeri, Mahbobeh ; Khoshvishkaie, Elnaz ; Eslami, Shahram

PURPOSELeishmaniasis is a major public health problem worldwide in many parts of the world. Current anti-leishmanial drugs have only limited clinical efficacy. Aurothiomalate derivatives are useful for treating rheumatoid arthritis, but have emerged as a promising therapeutic candidate for leishmaniasis. This paper gives a review of the literature about the usefulness of aurothiomalate derivatives against leishmaniasis.METHODSIn this study, we reviewed the proposed mechanisms of action of aurothiomalate and related compounds on the metabolism of L. major and collected data by searching relevant articles.RESULTSAurothiomalate-based drugs could be effective against leishmaniasis through two direct and indirect mechanisms: first, cytotoxic effects on parasites via thiomalate's false substrate role in the citric acid cycle against malate; and second, immunosuppressive and anti-inflammatory effects of aurothiomalate derivatives with prostaglandin production inhibitory effects.CONCLUSIONSThe current study documented that aurothiomalate-based drugs could be effective against leishmaniasis through two direct and indirect mechanisms of action. Gold thiomalate as a promising hit should be evaluated against L. major in vitro and in vivo conditions in the future.

100 Deals associated with Sodium Aurothiomalate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00992	Sodium Aurothiomalate	M01CB01	DB09276

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Rheumatoid Arthritis	JP	Takata Seiyaku Co., Ltd.	01 Oct 1970
Arthritis	-	Merck Sharp & Dohme Corp.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


Pubmed	Not Applicable	Rheumatoid Arthritis	174	Methotrexate (MTX)	zbrgmdtshw(oihkrcmrmz) = ievycmvhnm jhmnkfabnn (pwwnomvykt ) View more	-	01 Oct 1998
				Gold sodium thiomalate (GSTM)	zbrgmdtshw(oihkrcmrmz) = xgkafzcvfr jhmnkfabnn (pwwnomvykt ) View more